Processa Pharmaceuticals Inc PCSA

Healthcare

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).

NDAQ:PCSA - Post by User

Processa Pharmaceuticals Inc > PCSA..... go ahead .... I dare ya to Chase !

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon Jan 26, 2024 12:35pm

14 Views

Post# 35847264

RE:RE:RE:RE:PCSA..... go ahead .... I dare ya to Chase !

JUst to be perfectly clear..... I was wrong about my AH prediction on PCSA.....It actually went alot higher than I thought it would....my bad.

But in the end .... I was totally correct on my P.O call

Hope I saved a few portfolios

Cheers !

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for May 17, 2024